Abstract
Insomnia is a frequent climacteric symptom. This pilot, double-blind, randomized placebo-controlled trial compared estradiol
associated with trimegestone or placebo in 12 women with perimenopausal insomnia. The Pittsburgh Sleep Quality Index (PSQI)
was administered, and polysomnography was performed at baseline and after 28 days. Sleep efficiency and median score of the
PSQI improved significantly in the hormone therapy group (HT) (p = 0.041 and p = 0.027, respectively) and not in placebo group. Perimenopausal insomnia improved after short-term HT.
associated with trimegestone or placebo in 12 women with perimenopausal insomnia. The Pittsburgh Sleep Quality Index (PSQI)
was administered, and polysomnography was performed at baseline and after 28 days. Sleep efficiency and median score of the
PSQI improved significantly in the hormone therapy group (HT) (p = 0.041 and p = 0.027, respectively) and not in placebo group. Perimenopausal insomnia improved after short-term HT.
- Content Type Journal Article
- Category Short Communication
- Pages 1-4
- DOI 10.1007/s00737-011-0242-2
- Authors
- Betania Huber Silva, Postgraduate Program in Medical Sciences, UFRGS, Porto Alegre, Brazil
- Denis Martinez, Postgraduate Program in Medical Sciences, UFRGS, Porto Alegre, Brazil
- Maria Celeste Osório Wender, Postgraduate Program in Medical Sciences, UFRGS, Porto Alegre, Brazil
- Journal Archives of Women’s Mental Health
- Online ISSN 1435-1102
- Print ISSN 1434-1816